Blood Cancer News and Research RSS Feed - Blood Cancer News and Research

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone. [More]
Breakthrough in cancer cell screening advances personalised treatment of childhood leukaemia

Breakthrough in cancer cell screening advances personalised treatment of childhood leukaemia

Researchers at Newcastle University have been able to accurately predict how children whose cancer returns after treatment for leukaemia are likely to respond to further treatment. [More]
Scientists identify eight cancer types linked to excess weight and obesity

Scientists identify eight cancer types linked to excess weight and obesity

There's yet another reason to maintain a healthy weight as we age. An international team of researchers has identified eight additional types of cancer linked to excess weight and obesity: stomach, liver, gall bladder, pancreas, ovary, meningioma (a type of brain tumor), thyroid cancer and the blood cancer multiple myeloma. [More]
ICR researchers identify how genetic variant linked to leukaemia helps cancer cells survive

ICR researchers identify how genetic variant linked to leukaemia helps cancer cells survive

Scientists at The Institute of Cancer Research, London, have identified how an inherited genetic variant, associated with an increased risk of developing the most common type of leukaemia, helps cancer cells survive. The findings could lead to new ways to target the disease. [More]
Blood cancer is associated with considerably higher healthcare costs than other cancers

Blood cancer is associated with considerably higher healthcare costs than other cancers

Health economics studies, published today in The Lancet Haematology, report that the cost of treating blood cancers is twice that for treating other cancers. This is largely because they require more complex treatment regimens that necessitate longer hospital stays. [More]
GSK and University of Leicester team up to develop novel drugs to treat blood cancer

GSK and University of Leicester team up to develop novel drugs to treat blood cancer

A collaboration between the University of Leicester and global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer. [More]
TUM scientists discover molecular signaling pathway for self-destruction in leukemia cells

TUM scientists discover molecular signaling pathway for self-destruction in leukemia cells

When adults develop blood cancer, they are frequently diagnosed with what is referred to as acute myeloid leukemia. [More]
Scientists discover novel genetic mutation linked to osteonecrosis of femoral head

Scientists discover novel genetic mutation linked to osteonecrosis of femoral head

Scientists at the Research Institute of McGill University Health Centre have discovered a new genetic mutation linked to osteonecrosis of the hip, specifically the femoral head - the spherical-shaped mass at the top of the femur. [More]
New treatment approach may benefit relapsed post-transplant blood cancer patients

New treatment approach may benefit relapsed post-transplant blood cancer patients

For many patients with advanced blood cancers, a stem-cell transplant can drive the disease into remission. However, about one-third of these patients experience a relapse and face a very poor prognosis. [More]
Study shows how increase in BMI contributes to multiple myeloma growth and progression

Study shows how increase in BMI contributes to multiple myeloma growth and progression

In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients. [More]
Scientists reveal how common symptomless condition can develop into myeloma

Scientists reveal how common symptomless condition can develop into myeloma

Researchers from the University of Birmingham and hospitals across the West Midlands have revealed how a common symptomless condition can develop into the blood cancer myeloma. [More]
Scientists identify set of genes that could predict clinical outcomes in patients with FLT3-ITD AML

Scientists identify set of genes that could predict clinical outcomes in patients with FLT3-ITD AML

Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have identified a set of genes, including DNMT3A, that could potentially be used to predict clinical outcomes of patients who suffer from a type of Acute Myeloid Leukemia (AML) associated with an FLT3 internal tandem duplication (FLT3-ITD) mutation. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Researchers demonstrate simple approach to prove how classes of new drugs work

Researchers demonstrate simple approach to prove how classes of new drugs work

A collaborative effort by cancer researchers at Cold Spring Harbor Laboratory and chemists at Boehringer Ingelheim, a pharmaceutical firm, has resulted in the identification of a new drug target in leukemia and creation of a candidate drug that hits the target. [More]
Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists at the Friedrich Miescher Institute for Biomedical Research and the University of Basel have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. [More]
Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. [More]
PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. [More]
Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

We recently discovered a new form of an inherited deficiency of platelets, which is caused by mutations in the ETV6-gene. [More]
Researchers discover AF1q protein linked to multiple myeloma, EMD

Researchers discover AF1q protein linked to multiple myeloma, EMD

A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated with multiple myeloma and a condition that occurs in approximately one-fourth of very aggressive multiple myeloma, extramedullary disease or EMD. [More]
Joint research reveals key mechanisms of persistent latent infection of HTLV-1

Joint research reveals key mechanisms of persistent latent infection of HTLV-1

Joint research between scientists from Kumamoto University, Japan and Imperial College London, UK has revealed the mechanisms of persistent latent infection of the human T-cell leukemia virus type 1 (HTLV-1). [More]
Advertisement
Advertisement